296 related articles for article (PubMed ID: 12672176)
1. Zotepine in Huntington's disease.
Bonelli RM; Niederwieser G; Lahousen T; Hofmann P
Hum Psychopharmacol; 2003 Apr; 18(3):227-9. PubMed ID: 12672176
[TBL] [Abstract][Full Text] [Related]
2. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
[TBL] [Abstract][Full Text] [Related]
3. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
Kenney C; Hunter C; Davidson A; Jankovic J
Mov Disord; 2007 Jan; 22(1):10-3. PubMed ID: 17078062
[TBL] [Abstract][Full Text] [Related]
4. Unified Huntington's disease rating scale: a follow up.
Siesling S; van Vugt JP; Zwinderman KA; Kieburtz K; Roos RA
Mov Disord; 1998 Nov; 13(6):915-9. PubMed ID: 9827615
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.
Saft C; Lauter T; Kraus PH; Przuntek H; Andrich JE
BMC Neurol; 2006 Feb; 6():11. PubMed ID: 16507108
[TBL] [Abstract][Full Text] [Related]
7. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
Curtis A; Mitchell I; Patel S; Ives N; Rickards H
Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
[TBL] [Abstract][Full Text] [Related]
8. Amantadine in the akinetic-rigid variant of Huntington's disease.
Magnet MK; Bonelli RM; Kapfhammer HP
Ann Pharmacother; 2004; 38(7-8):1194-6. PubMed ID: 15178736
[TBL] [Abstract][Full Text] [Related]
9. The long-term effect of tetrabenazine in the management of Huntington disease.
Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR
Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408
[TBL] [Abstract][Full Text] [Related]
10. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.
Vitale C; Marconi S; Di Maio L; De Michele G; Longo K; Bonavita V; Barone P
Mov Disord; 2007 Dec; 22(16):2359-64. PubMed ID: 17894335
[TBL] [Abstract][Full Text] [Related]
11. High-dose olanzapine in Huntington's disease.
Bonelli RM; Niederwieser G; Tribl GG; Költringer P
Int Clin Psychopharmacol; 2002 Mar; 17(2):91-3. PubMed ID: 11890191
[TBL] [Abstract][Full Text] [Related]
12. A shortened version of the motor section of the Unified Huntington's Disease Rating Scale.
Siesling S; Zwinderman AH; van Vugt JP; Kieburtz K; Roos RA
Mov Disord; 1997 Mar; 12(2):229-34. PubMed ID: 9087982
[TBL] [Abstract][Full Text] [Related]
13. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
14. Complex movement behaviour and progression of Huntington's disease.
Andrich J; Saft C; Ostholt N; Müller T
Neurosci Lett; 2007 Apr; 416(3):272-4. PubMed ID: 17321683
[TBL] [Abstract][Full Text] [Related]
15. Unified Huntington's disease rating scale: clinical practice and a critical approach.
Klempír J; Klempírova O; Spacková N; Zidovská J; Roth J
Funct Neurol; 2006; 21(4):217-21. PubMed ID: 17367582
[TBL] [Abstract][Full Text] [Related]
16. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.
Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403
[TBL] [Abstract][Full Text] [Related]
17. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.
Mov Disord; 1996 Mar; 11(2):136-42. PubMed ID: 8684382
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine in Huntington's disease.
Paleacu D; Anca M; Giladi N
Acta Neurol Scand; 2002 Jun; 105(6):441-4. PubMed ID: 12027832
[TBL] [Abstract][Full Text] [Related]
19. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.
van Vugt JP; Siesling S; Vergeer M; van der Velde EA; Roos RA
J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):35-9. PubMed ID: 9221965
[TBL] [Abstract][Full Text] [Related]
20. Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease.
Kegelmeyer DA; Kloos AD; Fritz NE; Fiumedora MM; White SE; Kostyk SK
J Neurol Sci; 2014 Dec; 347(1-2):219-23. PubMed ID: 25456459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
